Neuroprotection in the MPTP parkinsonian C57BL/6 mouse model by a compound isolated from tobacco

Chemical Research in Toxicology

Volumn 14, Issue 5, 2001, Pages 523-527

  Castagnoli, Kay P ^a   Steyn, Stefanus J ^a   Petzer, Jacobus P ^a   Van Der Schyf, Cornelis J ^a   Castagnoli Jr , Neal ^a  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2,3,6 TRIMETHYL 1,4 NAPHTHOQUINONE; AMINE OXIDASE (FLAVIN CONTAINING); DOPAMINE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; NAPHTHOQUINONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOPAMINE BRAIN LEVEL; MALE; MOUSE; NEOSTRIATUM; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; SMOKING;

ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DOPAMINE; MICE; MICE, INBRED C57BL; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; NAPHTHOQUINONES; NEOSTRIATUM; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; PLANT EXTRACTS; PLANTS, TOXIC; TOBACCO;

ANIMALIA; GYMNOMYZA SAMOENSIS; NICOTIANA TABACUM; PARKINSONIA;

EID: 0035016740     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx000224v     Document Type: Article

References (45)

1. Agid, Y. (1991) Parkinson's Disease: pathophysiology. Lancet 337, 1321-1324.
2. Tanner, C. M., and Aston, D. A. (2000) Epidemiology of Parkinsons's disease and akinetic syndromes. Curr. Opin. Neurol. 13, 427-430.
3. Langston, J. W., Ballard, P., Tetrud, J. W., and Irwin, I. (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979-980.
4. Heikkila, R. E., Hess, A., and Duvoisin, R. C. (1984) Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 224, 1451-1453.
5. Royland, J. E., and Langston, J. W. (1998) MPTP: A Dopaminergic Neurotoxin. In Highly Selective Neurotoxins (Kostrzewa, R. M., Ed.) pp 142-143, Humana Press, Totowa, NJ.
6. Di Monte, D. A., Royland, J. E., Anderson, A., Castagnoli, K., Castagnoli, N., Jr., and Langston, J. W. (1997) Inhibition of monoamine oxidase contributes to the protective effect of 7-nitroindazole against MPTP neurotoxicity. J. Neurochem. 69, 1771-1773.
7. Castagnoli, K., Palmer, S., and Castagnoli, N., Jr. (1999) Neuroprotection by (R)-deprenyl and 7-nitroindazole in the MPTP C57BL/6 mouse model of neurotoxicity. Neurobiology 7, 135-149.
8. Chan, P., Di Monte, D. A., Langston, J. W., and Janson, A. M. (1997) (+)MK-801 does not prevent MPTP-induced loss of nigral neurons in mice. J. Pharmacol. Exp. Ther. 280, 439-446.
9. Royland, J. E., and Langston, J. W. (1998) MPTP: A Dopaminergic Neurotoxin. In Highly Selective Neurotoxins (Kostrzewa, R. M., Ed.) pp 144-169, Humana Press, Totowa, NJ.
10. Chiba, K., Peterson, L. A., Castagnoli, K. P., Trevor, A. J., and Castagnoli, N., Jr. (1985) Studies on the molecular mechanism of bioactivation of the selective nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Drug Metab. Dispos. 13, 342-347.
11. Alexi, T., Borlongan, C. V., Faull, R. L. M., Williams, C. E., Clark, R. G., Gluckman, P. D., and Hughes, P. E. (2000) Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases. Prog. Neurobiol. 60, 409-470.
12. Fuller, R. W., and Henrick-Luecke, S. K. (1984) Deprenyl protection against striatal dopamine depletion by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Res. Commun. Subst. Abuse 5, 241-246.
13. Heikkila, R. E., Manzino, L., Cabbat, F. S., and Duvoisin, R. C. (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311, 467-469.
14. Heikkila, R. E., Duvoisin, R. C., Finberg, J. P., and Youdim, M. B. (1985) Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur. J. Pharmacol. 116, 313-317.
15. Kindt, M. V., and Heikkila, R. E. (1986) Prevention of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic toxicity in mice by MDL 72145, a selective inhibitor of MAO-B. Life Sci. 38, 1459-1462.
16. Yu, P. H., Davis, B. A., Durden, D. A., Barber, A., Terleckyj, I., Nicklas, W. G., and Boulton, A. A. (1994) Neurochemical and neuroprotective effects of some aliphatic propargylamines: new selective nonamphetamine-like monoamine oxidase B inhibitors. J. Neurochem. 62, 697-704.
17. Calne, D. B. (1993) Treatment of Parkinson's Disease. N. Engl. J. Med. 14, 1021-1027.
18. Morens, D. M., Grandinetti, A., Reed, D., White, L. R., and Ross, G. W. (1995) Cigarette smoking and protection from Parkinson's disease: False association or etiologic clue? Neurology 45, 1041-1051.
19. Carr, L. A., and Rowell, P. P. (1990) Attenuation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity by tobacco smoke. Neuropharmacology 29, 311-314.
20. Essman, W. B. (1977) Serotonin and monoamine oxidase in mouse skin: Effects of cigarette smoke exposure. J. Med. 8, 95-101.
21. Norman, T. R., Chamberlain, K. G., French, M. A., and Burrows, G. D. (1982) Platelet monoamine oxidase activity and cigarette smoking. J. Affective Disord. 4, 73-77.
22. Carr, L. A., and Basham, J. K. (1991) Effects of tobacco smoke constituents on MPTP-induced toxicity and monoamine oxidase activity in the mouse brain. Life Sci. 48, 1173-1177.
23. Yu, P. H., and Boulton, A. A. (1987) Irreversible inhibition of monoamine oxidase by some components of cigarette smoke. Life Sci. 41, 675-682.
24. Oreland, L., Fowler, C. J., and Schalling, D. (1981) Low platelet monoamine oxidase activity in cigarette smokers. Life Sci. 29, 2511-2518.
25. Norman, T. R., Chamberlain, K. G., and French M. A. (1987) Platelet monoamine oxidase: Low activity in cigarette smokers. Psychiatry Res. 20, 199-205.
26. Berlin, I., Said, S., Spreux-Varoquaux, O., Olivares, R., Launay, J.-M., and Puech, A. J. (1995) Monoamine oxidase A and B activities in heavy smokers. Biol. Psychiatry 38, 756-761.
27. Fowler, J. S., Volkow, N. D., Wang, G. J., Pappas, N., Logan, J., Shea, C., Alexoff, D., MacGregor, R., Schlyer, D., Zezulkova, I., and Wolf, A. P. (1996) Brain monoamine oxidase A inhibition in cigarette smokers. Proc. Natl. Acad. Sci. U.S.A. 93, 14065-14069.
28. Fowler, J. S., Volkow, N. D., Wang, G. J., Pappas, N., Logan, J., MacGregor, R., Alexoff, D., Shea, C., Schlyer, D., and Wolf, A. P. (1996) Inhibition of monoamine oxidase B in the brains of smokers. Nature 379, 733-736.
29. Khalil, A. A., Steyn, S., and Castagnoli, N., Jr. (2000) Isolation and characterization of a monoamine oxidase inhibitor from tobacco leaves. Chem. Res. Toxicol. 13, 31-35.
30. Kimland, B., Appleton, A. J., Aasen, A. J., Roseraade, J., and Enzell, C. R. (1972) Neutral oxygen-containing volatile constituents of Greek tobacco. Phytochemistry 11, 309-316.
31. Chamberlain, W. J., and Stedman, R. L. (1986) Composition studies on tobacco. XXVIII. 2,3,6-Trimethyl-1,4-naphthoquinone in cigarette smoke. Phytochemistry 7, 1201-1203.
32. Pitts, S. M., Markey, S. P., Murphy, D. L., and Weisz, A. (1986) Recommended practices for the safe handling of MPTP. In MPTP: A Neurotoxin Producing a Parkinsonian Syndrome (Markey, S. P., Castagnoli, N., Jr., Trevor, A. J., and Kopin, I. J., Eds.) pp 703-716, Academic Press, New York.
33. Schmidle, C. J., and Mansfield, R. C. (1956) The aminomethylation of olefins. II. A new synthesis of 1-alkyl-4-aryl-4-piperidinols. J. Am. Chem. Soc. 78, 425-428.
34. 3. Angew. Chem., Int. Ed. 33, 2475-2477.
35. Gready, J. E., Hata, K., Kazumi, K., Sternhell, S., and Tansey, C. W. (1990) NMR study of bond orders in o- and p-quinones. Aust. J. Chem. 43, 593-600.
36. Wakamatsu, T., Nishi, T., Ohnuma, T., and Ban, Y. (1984) A convenient synthesis of Juglone via neutral salcomine oxidation. Synth. Commun. 14, 1167-1173.
37. Norris, R. K., and Sternhell, S. (1966) Long-range spin-spin coupling in 1,4-benzoquinones and some related compounds. Aust. J. Chem. 19, 617-627.
38. Hall, L., Murray, S., Castagnoli, K., and Castagnoli, N., Jr. (1992) Studies on 1,2,3,6-tetrahydropyridine derivatives as potential monoamine oxidase inactivators. Chem. Res. Toxicol. 5, 625-633.
39. Van der Schyf, C. J., Castagnoli, K., Palmer, S., Hazelwood, L., and Castagnoli, N., Jr. (2000) Melatonin fails to protect against long-term MPTP-induced dopamine depletion in mouse striatum. Neurotoxic. Res. 1, 261-269.
40. Fuller, R. W., and Hemrick-Luecke, S. K. (1985) Influence of selective, reversible inhibitors of monoamine oxidase on the prolonged depletion of striatal dopamine by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Life Sci. 37, 1089-1096.
41. Da Prada, M., Kettler, R., Keller, H. H., Bonetti, E. P., and Imhof, R. (1987) Ro 16-6491: a new reversible and highly selective MAO-B inhibitor protects mice from the dopaminergic neurotoxicity of MPTP. Adv. Neurol. 45, 175-178.
42. Matsumoto, J., Takahashi, T., Agata, M., Toyofuka, H., and Sasada, N. (1994) A study of the biological pharmacology of IFO, a new selective and reversible monoamine oxidase-B inhibitor. Jpn. J. Pharmacol. 65, 51-57.
43. Babbedge, R. C., Bland-Ward, P. A., Hart, S. L., and Moore, P. K. (1993) Inhibition of rat cerebellar nitric oxide synthase by 7-nitroindazole and related substituted indazoles. Br. J. Pharmacol. 110, 225-228.
44. Castagnoli, K., Palmer, S., Anderson, A., Bueters, T., and Castagnoli, N., Jr. (1997) The neuronal nitric oxide synthase inhibitor 7-nitroindazole also inhibits the monoamine oxidase-B-catalyzed oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Chem. Res. Toxicol. 10, 364-368.
45. Schulz, J. B., Matthews, R. T., Muqit, M. M. K., Browne, S. E., and Beal, M. R. (1995) Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J. Neurochem. 64, 936-939.